UBS Boosts Price Target on Bruker (BRKR) to $19
Tweet Send to a FriendGet Alerts BRKR Hot Sheet
Price: $17.36 --0%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 8
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 8
Trade BRKR Now!
UBS raised its price target on Buy-rated Bruker (NASDAQ: BRKR) from $16.50 to $19.
The firm comments, "We continue to believe that a global macroeconomy trending in the right direction and good organic growth momentum can drive solid results in the near-term, and that investors remain positive on the stock as an operational turn-around story. Shares currently trade at a discount to the tools avg – with BRKR at 1.4x fwd EV/sales vs. 2.8x for the life sciences group, and 9.1x fwd EV/EBITDA vs. 10.3x for the group."
For an analyst ratings summary and ratings history on Bruker click here. For more ratings news on Bruker click here.
Shares of Bruker closed at $16.77 yesterday, with a 52 week range of $9.91-$17.35.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We continue to believe that a global macroeconomy trending in the right direction and good organic growth momentum can drive solid results in the near-term, and that investors remain positive on the stock as an operational turn-around story. Shares currently trade at a discount to the tools avg – with BRKR at 1.4x fwd EV/sales vs. 2.8x for the life sciences group, and 9.1x fwd EV/EBITDA vs. 10.3x for the group."
For an analyst ratings summary and ratings history on Bruker click here. For more ratings news on Bruker click here.
Shares of Bruker closed at $16.77 yesterday, with a 52 week range of $9.91-$17.35.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Jefferies Bumps PT/Est. on AO Smith (AOS)
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
